SB-267268 is a selective, non-peptidic antagonist of αvβ3 and αvβ5 integrins, used to inhibit angiogenesis and VEGF expression; it reduces blood vessel profiles in the inner retina in vivo and inhibits vitronectin-mediated migration of human and rat aortic smooth-muscle cells as well as the attachment of αvβ3-transfected HEK293 cells to RGD-containing matrix proteins.